Medicine
Breyanzi kit
Breyanzi kit is a prescription medicine containing Lisocabtagene maraleucel, marketed by Juno Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store vials in the vapor phase of liquid nitrogen (less than or equal to minus…
Key facts
- Active ingredient (INN)
- Lisocabtagene maraleucel
- Brand
- Breyanzi
- Dosage form
- Kit
- Packs
- 1 kit
- Marketing authorisation holder
- Juno Therapeutics
- Manufacturer
- Juno Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store vials in the vapor phase of liquid nitrogen (less than or equal to minus 130°C) in a temperature-monitored system. • Thaw BREYANZI prior to infusion.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XL08 Lisocabtagene maraleucel
- HS code (indicative)
- 3002.51Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 5 February 2021
- Identifiers
- RxCUI 2479140, 2479145DailyMed set ID 594bb413-af3b-4b97-afb3-bfe2b174f2edNDC 73153-900Application BLA125714
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * 5 mL in 1 vial, single-dose * 5 mL in 1 vial, single-dose | 73153-900-01 | Juno Therapeutics | 5 February 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Lisocabtagene maraleucel is a prescription medicine indicated for the treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma. MedsAcross supplies Lisocabtagene maraleucel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Lisocabtagene maraleucelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- BREYANZI prescribing information (Juno Therapeutics) · U.S. National Library of Medicine, DailyMed
- Breyanzi: European public assessment report (EPAR) · European Medicines Agency
Need Breyanzi kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.